Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Osteoarthritis Across Multiple Joints (Wear-and-Tear Arthritis): Clinical Breakdown: Articular Cartilage Breakdown, Subchondral Sclerosis, Multi-Joint Distribution Patterns, Etiology, and Therapeutic Management

A rheumatology pathology reference on cartilage matrix breakdown, subchondral remodelling and osteophyte formation, the distribution across knees, hips, spine and hands, and the combination of non-drug, drug and surgical management.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • This is the strongest of the three osteoarthritis briefs. Its core clinical principle, that osteoarthritis is an active whole-joint disease rather than passive wear, is the single most important correction to the common understanding, and stating it first is the right editorial decision.
  • The pathophysiology is accurate. Chondrocytes do shift toward a degradative programme, matrix metalloproteinases and aggrecanases do outpace synthesis, and type II collagen and proteoglycans are lost. One sequence detail is worth adding: aggrecan is lost first, and because its charge is what draws water into the tissue, losing it costs cartilage its stiffness before the collagen network is damaged. Once the collagen is cut, the change is effectively irreversible.
  • The subchondral bone section is correct and misses the loop that makes it matter. Sclerotic bone is stiffer and absorbs shock less well, so it passes more load back to the remaining cartilage. That is one of several self-reinforcing cycles in osteoarthritis, and it explains why the disease progresses once established.
  • The brief does not say where the pain comes from, and this is the most clinically useful omission. Cartilage has no nerve supply, so wearing it away is not itself painful. Pain arises from subchondral bone, synovium, capsule, ligaments and surrounding muscle. This is why X-ray severity and symptoms correlate so poorly in both directions, and why treatment is aimed at function rather than at images.
  • Bone marrow lesions, visible on MRI, are among the structural features most consistently associated with pain, and belong in any current account of the pathology.
  • The distribution table is accurate and would be improved by noting which joints are spared. The ankle takes enormous load and is rarely affected without previous injury; the knuckles are typically spared while rheumatoid arthritis favours them. What is spared is diagnostic information, and it is also the clearest argument against the simple wear-and-tear model the brief is otherwise careful to reject.
  • Clinical presentation gives morning stiffness under 30 minutes, which is correct and deserves to be flagged as a discriminator rather than a description: inflammatory arthritis typically produces stiffness lasting an hour or more, and the distinction changes the entire diagnostic pathway.
  • The management section lists the right components and does not rank them. Guidelines place exercise, weight management and education as core treatment for everyone, with pharmacological therapy as an adjunct. Listing them in parallel understates how strong the exercise evidence is, with effect sizes for pain comparable to anti-inflammatory medicines and without the systemic risks.
  • Two specific points belong under therapy. Topical NSAIDs are preferred over oral for superficial joints because systemic absorption is low, which matters a great deal in older patients with kidney, cardiovascular or gastrointestinal risk. And arthroscopic debridement, lavage and resection of degenerative meniscal tears have repeatedly failed against placebo surgery and against exercise, and are not indicated for osteoarthritis.
  • Glucosamine and chondroitin are not mentioned. Given how widely they are used, a clinical reference is the right place to say that large trials have not demonstrated meaningful benefit.

Download the PDF

All source documents